Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  American Heart Journal

• Publication date

  2002-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1067/MHJ.2002.123581PMID 12094202
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention.

  2001cited by this paper
• Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention: Results of the GOLD (AU-Assessing Ultegra) Multicenter Study

  2001cited by this paper
• Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.

  2000cited by this paper
• Assessing the Optimal Level of Platelet Inhibition with GPIIb/IIIa Inhibitors in Patients Undergoing Coronary Intervention. Rationale and Design of the GOLD Study

  2000cited by this paper
• Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.

  1999cited by this paper
• State-of-the-Art Review : The Effect of Antiplatelet Drugs, Heparin, and Preanalytical Variables on Platelet Function Detected by the Platelet Function Analyzer (PFA-100®)

  1999cited by this paper
• Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention.

  1999cited by this paper
• Vascular access site complications after percutaneous coronary intervention with abciximab in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial.

  1998cited by this paper
• Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases.

  1998cited by this paper
• Glycoprotein IIb/IIIa integrin blockade.

  1998cited by this paper
• Monitoring platelet GP IIb/IIIa antagonist therapy.

  1998cited by this paper
• PFA-100™ System: A New Method for Assessment of Platelet Dysfunction

  1998cited by this paper
• Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease.

  1998cited by this paper
• Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates.

  1998cited by this paper
• Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade.

  1998cited by this paper
• Randomised placebo-controlled and balloon-angioplasty- controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade

  1998cited by this paper
• Progress in point-of-care laboratory testing for assessing platelet function.

  1998cited by this paper
• Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

  1998cited by this paper
• Monitoring platelet GP IIb/IIIa [corrected] antagonist therapy.

  1997cited by this paper
• Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.

  1997cited by this paper
• Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention : IMPACT-II

  1997cited by this paper
• Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.

  1997cited by this paper
• Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy.

  1997cited by this paper
• Monitoring platelet GP IIb/IIIa [corrected] antagonist therapy.

  1997cited by this paper
• Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.

  1997cited by this paper
• Characterization of an In Vitro Platelet Function Analyzer, PFA-100™

  1996cited by this paper
• Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators.

  1995cited by this paper
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.

  1994cited by this paper
• Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

  1994cited by this paper
• Simulation of primary haemostasis in vitro.

  1985cited by this paper

• Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: A narrative review.

  2019cites this paper
• Clinical Tests of Platelet Function

  2019cites this paper
• Point-of-Care Platelet Function Tests

  2015cites this paper
• Silica nanoparticles induced the pre-thrombotic state in rats via activation of coagulation factor XII and the JNK-NF-κB/AP-1 pathway

  2015cites this paper
• Glycoprotein IIb/IIIa inhibitors: an update on the mechanism of action and use of functional testing methods to assess antiplatelet efficacy.

  2011cites this paper
• Monitoring of Antithrombotic Therapies in Interventional Cardiology

  2010cites this paper
• Point-of-Care Assessment of Antiplatelet Agents in the Perioperative Period: A Review

  2009cites this paper
• The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation.

  2009cites this paper
• Platelet function analyzer (PFA-100) offers higher sensitivity and specificity than thromboelastography (TEG) in detection of platelet dysfunction.

  2009cites this paper
• Clinical Utility of the PFA-100

  2008cites this paper
• Pharmacologic Inhibition of Platelet Function

  2008cites this paper
• Development of platelet contractile force as a research and clinical measure of platelet function

  2007cites this paper
• Value of Platelet Activation Markers as Prothrombotic Risk Indicators

  2007cites this paper
• Measuring antiplatelet drug effects in the laboratory.

  2007cites this paper
• CHAPTER 23 – Clinical Tests of Platelet Function

  2007cites this paper
• CHAPTER 28 – The Platelet Function Analyzer (PFA)-100

  2007cites this paper
• Monitoring of the antiplatelet drugs effect in patients with coronary artery disease: what is the real clinical impact?

  2007cites this paper
• Baseline platelet reactivity in acute myocardial infarction treated with primary angioplasty--influence on myocardial reperfusion, left ventricular performance, and clinical events.

  2007cites this paper
• CLINICAL RESEARCH Interventional Cardiology Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention Insights Into the STRATEGY Study

  2006cites this paper
• Platelet function analyzer (PFA)‐100® closure time in the evaluation of platelet disorders and platelet function

  2006cites this paper
• Monitoring antiplatelet therapy during peripheral vascular and coronary interventions.

  2006cites this paper
• Single high-dose bolus tirofiban with high-loading-dose clopidogrel in primary coronary angioplasty

  2006cites this paper
• Current options in platelet function testing.

  2006cites this paper
• The platelet function analyzer (PFA-100): an update on its clinical use.

  2005cites this paper
• In vitro effects of gelatin solutions on platelet function: a comparison with hydroxyethyl starch solutions *

  2005cites this paper
• The platelet-function analyzer (PFA-100 ® ) for evaluating primary hemostasis

  2005cites this paper
• Variable inhibition of high-shear-induced platelet plug formation by eptifibatide and tirofiban under conditions of platelet activation and high von Willebrand release: a randomized, placebo-controlled, clinical trial.

  2004cites this paper
• Platelet Function Predicts Myocardial Damage in Patients With Acute Myocardial Infarction

  2004cites this paper
• Limited usefulness of the PFA-100™ for the monitoring of ADP receptor antagonists–in vitro experience

  2004cites this paper
• Is platelet aggregation a more important contributor than platelet adhesion to the overall platelet-related primary haemostasis measured by PFA-100?

  2003cites this paper
• Measurement of the effect of ticlopidine with the platelet function analyser (PFA-100) during coronary stent implantation.

  2003cites this paper
• Screening for the Risk for Bleeding or Thrombosis

  2003cites this paper